Sandro Cosconati
@scoscona
Followers
218
Following
1K
Statuses
128
RT @rsc_medchem: On the issue 1 cover is work by Sabrina Taliani, Floriana Morgillo, @scoscona & co on the discovery of c-MET/SMO modulator…
0
1
0
RT @JCIM_JCTC: Discovering Dually Active Anti-cancer Compounds with a Hybrid AI-structure-based Approach #DrugDiscovery
0
8
0
Our manuscript is now featured on the front cover of @JCIM_JCTC! Huge thanks to the talented @ben_nitro93 and @MicheleRoggia99 for creating this amazing cover art! #MyACSCover @ACS4Authors
0
3
13
@BiologyAIDaily @JCIM_JCTC Kudos to @MicheleRoggia99 and @ben_nitro93 for the efforts! PyRMD is here demonstrated for its predictive power in a challenging drug discovery task
0
0
4
RT @BiologyAIDaily: Discovering Dually Active Anti-cancer Compounds with a Hybrid AI-structure-based Approach @JCIM_JCTC 1/ In this study…
0
6
0
RT @EuroMedChem: 📣 Session 9 – Prof. Sandro COSCONATI from @unicampania is now on the stage for talk titled “From Reversible to Irreversibl…
0
2
0
RT @g_sbardella: Next talk in the peptide session at #EFMCISMC24 is given by Sandro Cosconati (@scoscona), describing his strategy to induc…
0
1
0
RT @JCIM_JCTC: Streamlining Large Chemical Library Docking with Artificial Intelligence: the PyRMD2Dock Approach #Docking #DrugDiscovery ht…
0
15
0
Take a peek at my cover art accepted for the 21 Dec issue of @CellChemBiol! Gratitude to @AIRC_it for supporting my research and shout-out to fellow authors @hildaApickett, @sadimaro80, and Alex Sobinoff. #drugdiscovery #CancerResearch
0
3
12
RT @CellChemBiol: Online now! Irreversible inhibition of TRF2TRFH recruiting functions by a covalent cyclic peptide induces telomeric repli…
0
2
0
Co-treatment with the G4 stabilizing agent RHPS4 amplifies APOD53's effects on telomeric replication stress, offering a potential combination strategy for cancer treatment. The interplay between TRFH targeting peptides and replication stress inducers is explored.
0
1
2
APOD53, a cysteine-binding acrylamide Michael acceptor modifier, forms covalent adducts with the TRF2TRFH peptide. Compared to its predecessor APOD41, APOD53 emerges as a more potent inhibitor of cellular viability, especially in cancer cells.
0
0
0
Thrilled to embark on a new journey as an @mculecom Aurora consultant! 🌐 Ready to contribute my expertise in medicinal chemistry to advance drug discovery. Check out my profile: #MCule #drugdiscovery #MedChem
1
0
3